Transaction · 0001447028-26-000058

Androski Lindsay

Androski Lindsay, PRES, reported a transaction classified as return at Arbutus Biopharma Corp involving 24655.000000 shares for an estimated $123275.00. Reported holdings after the transaction were 47682.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DPRES
ABUSArbutus Biopharma Corp
Filing timeOct 07
Trade dateOct 01, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableCalculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

ABUS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ABUS since 2026-10-07Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
return
Code D
Identifier
0001447028-26-000058
Common Shares
Transaction date
Oct 01, 2026
Filed Oct 07, 2026, 08:09 PM · 6d delay
Shares
24.6k sh
$5.00 per share
Estimated value
-$123k
Computed from shares × price
Holdings after
47.6k sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 6 calendar days after the transaction date.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Delayed Filing Direct Ownership Large Holdings Reduction
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.

Original filing · 0001447028-26-000058
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ABUS